Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

301.37 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Uber To $80? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
What's going on in today's session: S&P500 movers
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Stay informed with the top movers within the S&P500 index on Wednesday.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Why Amgen (AMGN) Stock Is Trading Up Today
Shares of biotech company Amgen (NASDAQ:AMGN) jumped 5.3% in the afternoon session after the company reported strong fourth-quarter results. Amgen exceeded analysts' revenue expectations this quarter,... 
Via StockStory
Amgen Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
Earnings Summary: Amgen Q4
 
Via Benzinga
Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday?
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data. 
Via Benzinga
Amgen Beat Fourth-Quarter Expectations. So, Why Did Shares Tumble?
In after-hours trades, Amgen stock fell around 2% following its fourth-quarter beat. 
Via Investor's Business Daily
Analyst Expectations For Amgen's Future
 
Via Benzinga
This Is What Whales Are Betting On Amgen
 
Via Benzinga
Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead
Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025. 
Via Benzinga
Topics Earnings
Earnings Miss? Amgen’s Dividend Still a Bright Spot
Via MarketBeat
Amgen (AMGN) Q4 2024 Earnings Call Transcript
AMGN earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Amgen Surpasses Q4 Earnings Forecasts
Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth. 
Via The Motley Fool
Amgen’s (NASDAQ:AMGN) Q4 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations
Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 10.9% year on year to $9.09 billion. The company’s full-year revenue guidance of... 
Via StockStory
These Were the 5 Top-Performing Stocks in the Dow Jones Industrial Average in January 2025
Via The Motley Fool
Topics Stocks
US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies. 
Via Benzinga
Earnings Scheduled For February 4, 2025
 
Via Benzinga
Markets React To Softening Trade Tariff Policy
Monday’s trading session resulted in slight negative closes across major indexes, but there’s good news here: whereas the Dow finished the trading day -122 points, it was -400 a half hour before this... 
Via Talk Markets
Topics Stocks Stocks / Equities
The Dogs Of The Dow 2025
The Dogs of the Dow is an investing strategy well-known to retail and institutional investors. 
Via Talk Markets
Topics Stocks Stocks / Equities
Friday's pre-market session: top gainers and losers in the S&P500 index
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
Via The Motley Fool
Topics Stocks
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
The Danish drug giant reported a 22% weight loss over 36 weeks. 
Via Investor's Business Daily
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals. 
Via Benzinga
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
Via The Motley Fool
Topics Stocks
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation
Amgen's Lumakras treatment, combined with Vectibix, is FDA-approved for KRAS G12C-mutated colorectal cancer. 
Via Benzinga
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Via The Motley Fool
What Lies Ahead In 2025? Slower Growth, More Volatility
As we move through 2025, the global economy and financial markets are facing a critical juncture. 
Via Talk Markets
Topics Economy Stocks / Equities
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.